Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply
- The CDC Reinstates Booster Dose of Hib Vaccine - SWIFTWATER, Pa., June 25 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ), announced today that the company has been able to increase the supply of its Hib-containing vaccines...Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Large Cardiovascular Outcomes Study To Be Initiated Manufacturing Comparability Analysis Complete: Exenatide Once Weekly NDA Submission Remains On Track SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., March 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), El...DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth
Strong Pipeline and Superior Distribution System Will Continue to Fuel Growth and Generate Cash NEW YORK, Feb. 10 /PRNewswire-FirstCall/ -- DuPont Group (NYSE: DD ) Vice President James C. Borel said today he expects DuPont business Pioneer Hi-Bred to grow its global seed corn market share ...deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
REYKJAVIK, Iceland, February 2 /PRNewswire-FirstCall/ -- Scientists from deCODE genetics (Nasdaq: DCGN ) today report the discovery of the first variation in the sequence of the human genome ever shown to confer increased risk of essential tremor. The single-letter variant (or SNP) was...Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
Third Quarter 2008 Revenue Increased 7 Percent to $3.9 Billion Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from Third Quarter 2007 GAAP Earnings Per Share of $0.18 Full Year Revenue Guidance Raised from $14.6 Billion - $14.9 Billion to ...BioLife Solutions Credit Facility Increased to $9 Million
Access to Additional Capital Will Enable Revenue Growth BOTHELL, Wash., Oct. 21 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and o...Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
EXTON, Pa., June 5 /PRNewswire/ -- BioTrends Research Group, Inc. released its third annual TreatmentTrends (TM): Psoriasis publication, providing insight into the management of psoriasis. This report is based on responses to an online survey completed by 102 US Dermatologists in April 2008. ...Nephrologists and Non-Nephrologists Alike Report Increased Attention on Chronic Kidney Disease
EXTON, Pa., May 23 /PRNewswire/ -- BioTrends Research Group, Inc. released a Special Report: "Referrals in Nephrology," providing insight into the referral patterns and co-management of patients with Chronic Kidney Disease (pre-dialysis) from the perspective of Nephrologists, Cardiologists, En...LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
LAGUNA HILLS, Calif., May 14 /PRNewswire-FirstCall/ -- LifeStem International, Inc., (OTC Bulletin Board: LSTM), formerly CalbaTech, Inc., an emerging life sciences company concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to ...APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
WASHINGTON, Feb. 13 /PRNewswire-USNewswire/ -- The following statement is attributable to Kathy Warye, CEO of the Association for Professionals in Infection Control and Epidemiology (APIC): "APIC is concerned with the increased rate of antibiotic resistant infections -- as high as 70 perce...Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007
BEIJING and CLAREMONT, Calif., Jan. 30 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) reports that the volume of bio-enhanced feed products sold during the fourth quarter of 2007 strengthened over the third quarter of 2007 and increased 25%...10,000 New Jobs, Investments Increased
FRANKFURT, Germany, May 12 /PRNewswire/ -- - German Chemical Parks Record Growth - Attractive Business Model for Investors The number of employees in German chemical parks has increased by roughly 10,000 to 240,000 between 2006 and 2008. In this same period, the number of compani...Alfalight Gets $3.8M From DARPA - Funding has increased to $8.5 Million
MADISON, Wis. . The Defense Advanced Research Projects Agency (DARPA), has awarded Alfalight a $3.9 million grant for Research and Development under the DARPA Super High Efficiency Diode Source (SHEDS) program. There are options that could increase the funding to a total award of $5.3 million. ...Wisconsin-based Third Wave reports increased revenue for 2003, fourth quarter
MADISON - Third Wave Technologies Inc. , a Madison-based provider of molecular diagnostics, reported fourth quarter and year-end earnings for 2003 last Tuesday. The year was transitional for Third Wave as the company focused its research, marketing and financial resources away from the genomic too...VC funding increased in third quarter with shining life sciences
Last week, we reviewed the IPO market based on data from Burrill & Co. By the way, Chicagoans will get not one but two chances to see and hear U.S. biotech guru Steve Burrill this coming week. He will be featured at the NanoCommerce event at McCormick Place in Chicago on Tuesday morning and he...cMaster RTplusPCR System for increased sensitivity and product length in RT-PCR
Abstract RT-PCR has become an essential method that allows researchers to determine the presence, structure and level of expression of an mRNA transcript in the organism, tissue or cell of interest. The basic protoc...SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
...279,571 for the same period in 2008. This decrease is primarily due to lower royalty income from our relationship with Perrigo. Royalty income increased 34%, or $59,017 to $230,789 in the three months ended June 30, 2009, compared to $171,772 for the first quarter of 2009. This increase is a result of ...Novavax Reports Second Quarter 2009 Financial Results
...rove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; the success of the Company's foreign joint venture and licensing agreements; the Company's ability to enter into future collaborations with ind...American Oriental Bioengineering Reports Second Quarter 2009 Financial Results
...-Asia-FirstCall/ -- --2Q09 Revenue increased 20.7% YoY to $71.2 Million-- --2Q09 Net Incom...2009. Revenue in the second quarter of 2009 increased 20.7% to $71.2 million from $59.0 million in the s...al products. Revenue from pharmaceutical products increased 17.4% to $58.4 million from $49.8 million in the p...GenVec Reports Second Quarter 2009 Financial Results
... revenues associated with our FMD and malaria programs, partially offset by increased revenue associated with our HIV program, as compared to the comparable prio... in revenue associated with our HIV program in each period is due mainly to increased research and process development efforts as compared to the comparable prio...SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
...es of $15.1 million for the second quarter of 2009 increased from $10.6 million for the second quarter of 2008 as a result of increased legal expenses, higher FAS123(R) expenses, higher ...o $57 million. The increase in burn rate is due to increased legal expenses, and...OncoGenex Reports Second Quarter 2009 Financial Results
...able to common shareholders for the second quarter increased to $4.6 million from $2.9 million in 2008. For the... 2009 the loss attributable to common shareholders increased to $7.0 million from $5.4 million in 2008. Resea...ch and development expenses for the second quarter increased to $3.6 million from $1.1 million in 2008. For the...Repligen Reports First Quarter Fiscal Year 2010 Financial Results
...This increase in operating expenses of $787,000 was primarily the result of increased spending associated with advancement of both our Phase 3 clinical trial of ...nd our Phase 2b clinical trial of RG2417 for bipolar depression, as well as increased research and development expenses associated with our preclinical HDAC inhi...The Breast Cancer Therapeutics Market in Australia
.../ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most...on developing targeted breast cancer therapies that offer patients not only increased efficacy, but reduced side effects as well," explains Carole Gaffud, Frost ...PDI Reports 2009 Second Quarter Financial Results
...ear ago period. These declines are primarily due to lower revenue. The overall increase in second quarter 2009 gross profit margin was attributable to increased gross profit in the Product Commercialization Services segment. This segment recognized a negative gross profit of $5.0 million in 2008 related to the...